Clinical Trial Update: Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function [Phase 2]

View source ↗

Summary

OPN-305 was evaluated in a Phase 2 placebo-controlled trial to prevent delayed graft function after kidney transplantation. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function

Drugs mentioned

• OPN-305 (OPN-305)

Snippet

Sponsor: Opsona Therapeutics Ltd. | Conditions: Delayed Graft Function | Phase 2 | Status: COMPLETED